Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
While at the University of Geneva, I focused on researching leukocyte migration and vascular biology in the context of inflammatory diseases and cancer. Our work led to the discovery and subsequent study of various adhesion molecules, including CD31, JAM-C, Olfml-3, and integrins, all of which play critical roles in these biological functions. As a result of our research, the university has filed several patents encompassing monoclonal antibodies (e.g., those that block JAM-C and Olfml-3) and small molecules that target CD31. Building upon this foundation, multiple start-up companies have been established. I aim to examine how innovation and project-oriented research are managed in our academic laboratory, start-up companies, and large pharmaceutical industries by drawing upon real-world examples.
